Ahmed Abdul Bari Hazari

Abstract

Background: Chronic Obstructive Pulmonary Disease affects more than 15 million Americans, with the majority of the patients more than 50 years old with current or past smokers. Objective: To study the safety and efficacy of Tiotropium bromide inhalation in both COPD & Bronchial Asthma patients. Materials and Methods: The present study was conducted in patients with stable as well as exacerbated COPD and Br. Asthma at Shadan Hospital, Telangana. Results: Significant improvement in Forced expiratory volume with respect to baseline at the end of the 14th week. The maximum mean response in FEV1 improved by 0.221, (68.03%) when the compared value of baseline 0.13L (p-value < 0> compared to COPD treatment group. The Forced expiratory volume (FEV1), Forced vital capacity (FVC) and FEV1/FVC ratio were improved with respect to baseline. Conclusion: Tiotropium via dry powder inhaler result in 24 hr bronchodilation as well as consistent and sustained improvement for both the COPD and the Bronchial Asthma patients. Keywords: Bronchial asthma, COPD, FEV1, FVC, FEV1/FVC ratio.

View Article

Abstract

Introduction: Tiotropium is well tolerated, with a safety profile comparable with that of placebo. Objective: To know the safety and efficacy of Tiotropium bromide compared with placebo. Material and Methods: The present clinical study was conducted in patients with stable as well as exacerbated COPD and Br. Asthma at Shadan Hospital, Telengana State from May 2015 to Feb 2016. Results: In case of Br. Asthma patient (n-10), the FEV­1 improved to 0.18 L (26.16%) with respect to baseline 0.15 L (P value < 0>1/FVC ratio is improved by 65.10% (5.51%) with respect to the baseline 61.70% (Pth weeks of period. In case of COPD patients the FEV1 is improved by 0.17 L (23.64%) with respect to baseline 0.14 L (P value < 0>1/FVC value improved by 64.72% (7.11%) with respect to the baseline 60.42% (P value < 0> Conclusion: In spirometric as well as clinically, placebo in COPD group patients (n-7) and Br. Asthma group patients (n-10) showed very less improvement, which is statistically not significant. Keywords: Bronchial Asthama, COPD, Placebo, FEV­1, FEV1/FVC, FVC.

View Article